KNP-502 (OCT-598)
Phase 1An EP2/EP4 inhibitor licensed to Oscotec; dosing in a Phase 1 solid-tumor trial began in late 2025.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals A licensed candidate has entered Phase 1, and partnered development of its bispecific ADC has widened.
Roles often seen at this stageResearch & development · BD & licensing · Clinical & PV
A drug developer founded in February 2019 that works on bispecific immuno-oncology antibodies and ADCs aimed at the tumor microenvironment; listed on KOSDAQ in March 2026.
An EP2/EP4 inhibitor licensed to Oscotec; dosing in a Phase 1 solid-tumor trial began in late 2025.
A bispecific ADC targeting both EGFR and cMET; GC Corp exercised its co-development option, and Kanaph leads CMC development.
A preclinical bispecific antibody for macular degeneration targeting C3b and VEGF.
A cancer candidate built as a fusion protein of FAP and a modified IL-12.
GC Corp exercised its option to co-develop the EGFR/cMET bispecific ADC.
Listed on the KOSDAQ market.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.